DK1443938T3 - Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse - Google Patents

Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse

Info

Publication number
DK1443938T3
DK1443938T3 DK02780083.8T DK02780083T DK1443938T3 DK 1443938 T3 DK1443938 T3 DK 1443938T3 DK 02780083 T DK02780083 T DK 02780083T DK 1443938 T3 DK1443938 T3 DK 1443938T3
Authority
DK
Denmark
Prior art keywords
prostaglantin
constipation
analogue
treatment
dosage unit
Prior art date
Application number
DK02780083.8T
Other languages
English (en)
Inventor
Myra L Patchen
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1443938(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK1443938T3 publication Critical patent/DK1443938T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings
DK02780083.8T 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse DK1443938T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14
PCT/JP2002/011862 WO2003041716A1 (en) 2001-11-14 2002-11-14 Dosage unit comprising a prostaglandin analog for treating constipation

Publications (1)

Publication Number Publication Date
DK1443938T3 true DK1443938T3 (da) 2011-09-26

Family

ID=23293447

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10010211.0T DK2298314T3 (da) 2001-11-14 2002-11-14 Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse
DK02780083.8T DK1443938T3 (da) 2001-11-14 2002-11-14 Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10010211.0T DK2298314T3 (da) 2001-11-14 2002-11-14 Doseringsenhed omfattende en prostaglandin-analog til behandling af forstoppelse

Country Status (15)

Country Link
US (3) US8097653B2 (da)
EP (2) EP2298314B1 (da)
JP (2) JP4852229B2 (da)
AR (3) AR037524A1 (da)
AT (1) ATE522218T1 (da)
BR (1) BR0214075A (da)
CA (1) CA2464420C (da)
CY (1) CY1115856T1 (da)
DK (2) DK2298314T3 (da)
ES (2) ES2368729T3 (da)
HK (1) HK1155649A1 (da)
LU (1) LU92826I2 (da)
PT (2) PT2298314E (da)
TW (1) TWI331920B (da)
WO (1) WO2003041716A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
PL1871380T3 (pl) * 2005-04-12 2012-03-30 Sucampo Ag Zastosowanie kombinacji związku prostaglandyny i inhibitora pompy protonowej w leczeniu zaburzeń żołądkowo-jelitowych
EP1978944B1 (en) * 2006-01-24 2012-08-15 R-Tech Ueno, Ltd. Soft-gelatin capsule formulation
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20110071163A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) * 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
DE69213057T2 (de) * 1991-03-14 1997-01-09 R Tech Ueno Ltd Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
PH31171A (en) * 1992-02-04 1998-03-20 Esai Co Ltd Aminobenzonic acid derivatives useful for treatinggastrointestinal conditions.
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
DE69714698T2 (de) * 1996-06-10 2002-12-05 Sucampo Ag Endothelin-antagonisten
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
AU739343B2 (en) 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
JP4332316B2 (ja) * 1999-10-15 2009-09-16 スキャンポ・アーゲー 二環式化合物組成物およびその安定化方法
AU4472701A (en) 2000-04-06 2001-10-23 Sucampo Ag Bile secretion promoting composition
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
BR0209863A (pt) 2001-05-18 2004-06-08 Sucampo Ag Composição catártica
BR0212233A (pt) 2001-08-31 2004-10-05 Sucampo Ag Abridor de canal de cloreto
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
CA2510051C (en) 2002-12-27 2016-07-05 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Also Published As

Publication number Publication date
DK2298314T3 (da) 2014-12-01
ES2524369T3 (es) 2014-12-05
HK1155649A1 (en) 2012-05-25
JP2011201905A (ja) 2011-10-13
LU92826I2 (fr) 2015-11-24
JP2005513014A (ja) 2005-05-12
CA2464420A1 (en) 2003-05-22
AR098997A2 (es) 2016-06-22
PT2298314E (pt) 2014-12-03
US20030119898A1 (en) 2003-06-26
US8389542B2 (en) 2013-03-05
AR037524A1 (es) 2004-11-17
EP2298314A1 (en) 2011-03-23
TWI331920B (en) 2010-10-21
EP1443938A1 (en) 2004-08-11
BR0214075A (pt) 2004-09-28
PT1443938E (pt) 2011-09-27
US20120088824A1 (en) 2012-04-12
ES2368729T3 (es) 2011-11-21
AR117404A2 (es) 2021-08-04
ATE522218T1 (de) 2011-09-15
JP4852229B2 (ja) 2012-01-11
CA2464420C (en) 2011-12-13
CY1115856T1 (el) 2017-01-25
TW200300091A (en) 2003-05-16
EP2298314B1 (en) 2014-09-03
US8097653B2 (en) 2012-01-17
WO2003041716A1 (en) 2003-05-22
EP1443938B1 (en) 2011-08-31
US20130143958A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
DK1158992T3 (da) Anvendelse af xenon til fremstilling af et farmaceutisk præparat til behandling af neurointoksikationer
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
DK1420759T3 (da) Farmaceutiske sammensætninger til behandling af astma
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
DK1425001T3 (da) Phenethanolaminderivater til behandling af respiratoriske sygdomme
EE200300239A (et) Rosuvastatiini (ZD4522) kasutamine heterosügootseperekondliku hüperkolesteroleemia raviks
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DK1443938T3 (da) Dosisenhed omfattende en prostaglantinanalog til behandling af forstoppelse
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20033205L (no) Terapeutiske kromanforbindelser
DK1349580T3 (da) Fremgangsmåde til forbedring af stabiliteten af en farmaceutisk sammensætning
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
DE50209245D1 (de) Neuroprotektives medikament
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776D0 (no) Hydroksyfenyl-piperazinyl-metyl-benzamidderivater til behandling av smerte
DK1150681T3 (da) Anvendelse af en farmaceutisk sammensætning indeholdende desoxypeganin til behandling af nikotinafhængighed
DK1446107T3 (da) Fremgangsmåde til fremstilling af tabletter omfattende s-adenosylmethionin
DK1200114T3 (da) PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1268482T3 (da) Pyranoindoler til behandling af glaukom